Living Lab Ventures, the corporate venture capital arm of Sinar Mas Land, has announced a significant investment in INCREASE Laboratorium Indonesia, a clinical research and laboratory firm located in BSD City. This investment aims to enhance Indonesia”s capacity for conducting internationally standardized clinical trials and to elevate the nation”s position in the biomedical innovation sector.
The funding will facilitate the expansion of INCREASE”s operations, foster the development of global partnerships, and support the pursuit of international certifications. The company is strategically positioned to meet the rising regional demand for high-quality research services.
INCREASE provides a full spectrum of clinical research solutions, which include study design, regulatory affairs, clinical testing, and bioanalytical testing. According to a statement from Living Lab Ventures, the company”s robust infrastructure, regulatory knowledge, and skilled workforce make it an ideal partner for global pharmaceutical and biotechnology companies seeking a research base in Southeast Asia.
“Indonesia has the potential to become a regional powerhouse in health and biomedicine,” stated Bayu Seto, Partner at Living Lab Ventures. “We view INCREASE as a strategic platform that can stimulate the national clinical research ecosystem, attract international partners, and enhance the competitiveness of Indonesia”s healthcare sector.”
As the healthcare landscape in Southeast Asia continues to evolve, the importance of Indonesia”s clinical research sector is becoming increasingly evident. A report from 6Wresearch indicates that the country”s Contract Research Organisation (CRO) market is anticipated to reach the billion-dollar mark by 2030, with a compound annual growth rate of 10.6% from 2024. This growth is propelled by the demand for efficient, scalable, and compliant research infrastructure to support advancements in biopharmaceuticals, medical technology, and academic research.
Current projects at INCREASE involve collaborations with clients from Indonesia, Singapore, Australia, and China. The firm has established research partnerships with Tsinghua University in China and Osaka University in Japan to promote technology transfer, joint research and development, and training for local talent.
To gain international recognition, INCREASE is actively working towards acquiring certifications from the College of American Pathologists (CAP), ISO 9001:2015, ISO 17025:2017, and ISO 15189:2022.
For Living Lab Ventures and its parent company, Sinar Mas Land, this investment aligns with a broader vision of transforming BSD City into a leading global innovation district. “This investment reflects our belief that the intersection of science, technology, and infrastructure will be crucial in positioning Indonesia on the global medical innovation map,” commented Mulyawan Gani, CEO of Digital Business at Sinar Mas Land.
The Biomedical Campus and D-HUB Special Economic Zone in BSD City are pivotal to this initiative, providing a platform for companies to integrate Internet of Things (IoT), artificial intelligence (AI), and other cutting-edge technologies into healthcare solutions.
